Candel Therapeutics
CADL· Manufacturing· Fiscal year ends in December
Paul Peter Tak, M.D. is the CEO of Candel Therapeutics.
Executives3
See all- 1Charles SchochChief Financial OfficerNot disclosed
- 2Francesca Barone, M.D.Ph.D. Chief Scientific OfficerNot disclosed
- 3Paul Peter Tak, M.D.Ph.D., FMedSci, Chief Executive OfficerNot disclosed
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Candel Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board6
See all- Paul B. ManningChair · 7 yr on the boardIndependentCompensation—Paid as an executive
- Edward J. Benz, Jr., M.DDirector · 8 yr on the boardIndependentNominating and Corporate Governance (Chair)—Paid as an executive
- Christopher MartellDirector · 7 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive
- Gary J. Nabel, M.D., Ph.D.Director · 3 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive
- Renee GaetaDirector · 3 yr on the boardIndependentAudit (Chair)—Paid as an executive
- Maha Radhakrishnan, M.D.Director · 0 yr on the boardIndependentAudit—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 29, 2026 | FY2025 |
| Annual report | 10-K | Mar 12, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 29, 2025 | FY2024 |
| Annual report | 10-K | Mar 13, 2025 | FY2024 |
| Proxy statement | DEF 14A | May 30, 2024 | FY2023 |
| Annual report | 10-K | Mar 28, 2024 | FY2023 |
